Provided by Tiger Trade Technology Pte. Ltd.

Acurx Pharmaceuticals, LLC*

1.47
+0.02001.38%
Post-market: 1.480.0100+0.68%19:17 EDT
Volume:84.59K
Turnover:126.11K
Market Cap:7.75M
PE:-0.48
High:1.53
Open:1.45
Low:1.45
Close:1.45
52wk High:8.34
52wk Low:1.31
Shares:5.27M
Float Shares:4.17M
Volume Ratio:0.18
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0454
EPS(LYR):-5.3153
ROE:-128.11%
ROA:-55.92%
PB:0.95
PE(LYR):-0.28

Loading ...

Acurx Pharmaceuticals - FDA Open to Pre-Nda Discussion After Single Phase 3 Trial if Efficacy Results are Robust

THOMSON REUTERS
·
Aug 03

Acurx Launches Pilot Trial of Ibezapolstat in Multiply Recurrent C. Difficile Infection

Reuters
·
Jul 14

Acurx Pharmaceuticals Posts Presentation on Ibezapolstat Microbiome Restoration Potential in Recurrent C. Difficile Infection

Reuters
·
Jul 13

Acurx Pharmaceuticals to Discuss Q2 Financial Results on Conference Call

Reuters
·
Jul 08

Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update

THOMSON REUTERS
·
Jul 08

Acurx says lead antibiotic ibezapolstat is ready to enter pivotal Phase 3 trials for C. difficile infection

Reuters
·
Jun 16

Acurx Pharmaceuticals Announces Presentation of Results From Leiden University Medical Center Public-Private Partnership for Its DNA Pol Iiic Inhibitors at the Leiden Early Drug Discovery & Development (Led3) Scientific Conference

THOMSON REUTERS
·
Jun 16

Analysts Conflicted on These Healthcare Names: Altimmune (ALT) and Acurx Pharmaceuticals (ACXP)

TIPRANKS
·
May 14

Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE)

TIPRANKS
·
May 13

Acurx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Acurx Pharmaceuticals Q1 EPS USD -0.62

THOMSON REUTERS
·
May 12

Acurx Q1 net loss narrows 22% to $1.68 million

Reuters
·
May 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 11

Acurx Pharmaceuticals Inc expected to post a loss of 63 cents a share - Earnings Preview

Reuters
·
May 08

Acurx DNA pol IIIC inhibitors spare gut microbiome in MRSA mouse study, poster shows

Reuters
·
May 04

Acurx CEO to join Alliance Global Partners Healthcare Company Showcase fireside chat

Reuters
·
Apr 29

BRIEF-Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update

Reuters
·
Apr 20

Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update

THOMSON REUTERS
·
Apr 20

BRIEF-Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Reuters
·
Apr 17

Acurx announces $7.1M registered direct offering priced at-the-market

TIPRANKS
·
Apr 16